text
stringlengths 7
742
| label
class label 2
classes |
|---|---|
He was diagnosed with possible serotonin syndrome; his symptoms resolved after clomipramine was stopped but before clozapine was restarted eight days later. | 1Related
|
OBJECTIVE: To report on the possible development of serotonin syndrome in a patient receiving clomipramine after clozapine was withdrawn from the treatment regimen. | 1Related
|
OBJECTIVE: To report on the possible development of serotonin syndrome in a patient receiving clomipramine after clozapine was withdrawn from the treatment regimen. | 1Related
|
Possible serotonin syndrome associated with clomipramine after withdrawal of clozapine. | 1Related
|
Possible serotonin syndrome associated with clomipramine after withdrawal of clozapine. | 1Related
|
The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused. | 1Related
|
The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused. | 1Related
|
The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused. | 1Related
|
The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused. | 1Related
|
The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused. | 1Related
|
The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused. | 1Related
|
The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused. | 1Related
|
The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused. | 1Related
|
The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused. | 1Related
|
The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused. | 1Related
|
The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused. | 1Related
|
The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused. | 1Related
|
Quinine induced coagulopathy--a near fatal experience. | 1Related
|
The cause of his bleeding was a severe thrombocytopoaenia, induced by chronic ingestion of quinine. | 1Related
|
Dose-dependent olanzapine-associated leukopenia: three case reports. | 1Related
|
These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related. | 1Related
|
These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related. | 1Related
|
We report three cases of patients who developed leukopenia during olanzapine treatment. | 1Related
|
CONCLUSION: This case illustrates a potential link between dermatologic and ocular 5-FU toxicities. | 1Related
|
Differential diagnoses included ocular rosacea with cicatrizing conjunctivitis and 5-FU-induced ectropion. | 1Related
|
DISCUSSION: Patients with 5-FU-induced ectropion experience tender, red, scaled lids, making contact lens wear difficult. | 1Related
|
DISCUSSION: Patients with 5-FU-induced ectropion experience tender, red, scaled lids, making contact lens wear difficult. | 1Related
|
Ectropion secondary to bolus injection of 5-fluorouracil. | 1Related
|
Exacerbation of 5-FU dermatologic toxicities in patients with preexisting conditions suggests the importance of aggressive ocular prophylaxis, using frequent ocular lubrication and topical steroid preparations with concurrent medical management of pre-existing dermatologic conditions. | 1Related
|
Presented is a case of acute renal failure induced by acetazolamide therapy for glaucoma. | 1Related
|
Renal failure associated with acetazolamide therapy for glaucoma. | 1Related
|
This sulfonamide like nephropathy should be differentiated from acetazolamide-related calcium phosphate nephrolithiasis. | 1Related
|
Ischaemic colitis in a patient taking meloxicam. | 1Related
|
Symptoms and endoscopic lesions quickly regressed within 1 week of meloxicam withdrawal. | 1Related
|
We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis. | 1Related
|
We suggest that meloxicam might have intestinal toxic effects when taken in high doses, because of reduced COX-2 selectivity. | 1Related
|
As these cases revealed, close monitoring of blood chemistry is mandatory after starting spironolactone, and patients should be advised to stop spironolactone immediately if diarrhoea develops. | 1Related
|
In patients with chronic heart failure, spironolactone added to conventional treatment may lead to serious and, occasionally, fatal hyperkalaemia. | 1Related
|
In some cases this seems to happen because spironolactone causes diarrhoea. | 1Related
|
Serious adverse events experienced by patients with chronic heart failure taking spironolactone. | 1Related
|
We report a patient with advanced colonic carcinoma who was treated with concomitant chemoirradiation with oxaliplatin and developed a peculiar dermnatitis in the irradiated field after being exposed to subsequent chemotherapy with oxaliplatin. | 1Related
|
An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease. | 1Related
|
Clofazimine enteropathy caused by crystal deposition can be life-threatening. | 1Related
|
Clofazimine enteropathy caused by crystal deposition can be life-threatening. | 1Related
|
Clofazimine enteropathy in a pediatric bone marrow transplant recipient. | 1Related
|
She developed a severe urticarial rash 3 weeks following initiation of therapy with Enoxaparin. | 1Related
|
We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication. | 1Related
|
We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication. | 1Related
|
We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication. | 1Related
|
We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication. | 1Related
|
Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation. | 1Related
|
We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation. | 1Related
|
CONCLUSION: The present findings suggest that fluvoxamine can cause increased libido in some patients. | 1Related
|
Increased libido in a woman treated with fluvoxamine: a case report. | 1Related
|
OBJECTIVE: The aim of this paper is to describe a case of increased libido during fluvoxamine therapy. | 1Related
|
RESULTS: The patient, a 27-year-old married Japanese woman with borderline personality disorder, developed an increased libido with the administration of fluvoxamine. | 1Related
|
The increased libido disappeared after fluvoxamine was discontinued. | 1Related
|
An infant who developed pancreatitis during meglumine antimoniate treatment for visceral leishmaniasis and who was successfully treated with a combination of allopurinol and ketoconazole is reported. | 1Related
|
Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate. | 1Related
|
CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology. | 1Related
|
Further studies are necessary to evaluate whether the study of HLA antigens may be a very useful tool to detect the patients with a predisposition to develop autoimmune thyroiditis, in order to make a early diagnosis of thyroid disorders during the IFN-alpha treatment. | 1Related
|
Further studies are necessary to evaluate whether the study of HLA antigens may be a very useful tool to detect the patients with a predisposition to develop autoimmune thyroiditis, in order to make a early diagnosis of thyroid disorders during the IFN-alpha treatment. | 1Related
|
Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease. | 1Related
|
OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease. | 1Related
|
OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease. | 1Related
|
During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. | 1Related
|
During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. | 1Related
|
Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses. | 1Related
|
Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses. | 1Related
|
Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses. | 1Related
|
Motor fluctuations appear after 2-3 years of levodopa treatment, and affect at least 50% of patients after five years. | 1Related
|
CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide. | 1Related
|
Leflunomide-associated weight loss in rheumatoid arthritis. | 1Related
|
METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000. | 1Related
|
OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center. | 1Related
|
RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies. | 1Related
|
It is increasingly recognized that dose adjustment of oral valacyclovir in renal failure is necessary to avoid neurotoxicity. | 1Related
|
Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study. | 1Related
|
She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection. | 1Related
|
Avascular necrosis of the femoral head in patients with prostate cancer treated with cyproterone acetate and radiotherapy. | 1Related
|
We report the case histories of two patients with histologically confirmed adenocarcinoma of the prostate, both of whom had been treated with steroidal anti-androgen therapy in the form of cyproterone acetate prior to radical or palliative pelvic irradiation, and who subsequently developed femoral head avascular necrosis. | 1Related
|
Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval. | 1Related
|
We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias. | 1Related
|
So far, few cases of pulmonary side effects caused by ticlopidine have been reported. | 1Related
|
Special care should be taken when pulmonary symptoms appear in association with ticlopidine treatment. | 1Related
|
Ticlopidine-induced interstitial pulmonary disease: a case report. | 1Related
|
We report a case of interstitial pulmonary disease that occurred together with lymphocytic colitis during treatment with ticlopidine. | 1Related
|
We report a case of interstitial pulmonary disease that occurred together with lymphocytic colitis during treatment with ticlopidine. | 1Related
|
A patient that received methadone for cancer-associated pain developed myoclonus as a side effect. | 1Related
|
Methadone-induced myoclonus in advanced cancer. | 1Related
|
OBJECTIVE: To report a case of fatal hyperkalemia owing to succinylcholine administration in a patient with mucositis secondary to chemotherapy. | 1Related
|
Succinylcholine-induced hyperkalemia in a patient with mucositis secondary to chemotherapy. | 1Related
|
We believe that mucositis was a contributing factor to this case of fatal hyperkalemia after administration of succinylcholine, with a mechanism similar to that reported with thermal injury. | 1Related
|
Cutaneous seeding after ultrasound-guided percutaneous ethanol injection for treatment of hepatocellular carcinoma. | 1Related
|
We describe a case of needle-track cutaneous seeding of hepatocellular carcinoma (HCC) after sonographically guided percutaneous ethanol injection (PEI). | 1Related
|
Adenosine-induced ventricular fibrillation. | 1Related
|
However, adenosine shortens the antegrade refractoriness of accessory atrioventricular connections and may cause acceleration of the ventricular rate during atrial fibrillation. | 1Related
|
We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine. | 1Related
|
After the dose of methylprednisolone was reduced from 40 mg to 20 mg i.v. q6h and shifted to other anti-asthma treatment by procaterol metered dose inhaler via spacer, the psychotic reaction disappeared a few hours later. | 1Related
|
Continuous EEG monitoring is helpful in managing seizures that occur as a complication of CBZ OD, after the course of recovery or worsening, and in providing assistance with prognosis. | 1Related
|